/
RSS Feed
ATLANTA, GA—Solid confirmation of target hematocrit to minimise clotting risks in polycythemia vera has been presented at the American Society of Hematology annual meeting and simultaneously published in the New England Journal of Medicine. Professor Tiziano Barbui Scientific Director of the Research Foundation at Ospedali Riuniti in Bergamo, Italy, discussed his research findings — justifying aggressive hematocrit reduction to below 45% — with Peter Goodwin.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/121207TizianoBarbuiPODCASTLoRes.mp3]
